Trend Pharma: payers demand real-world value while regulators tighten scrutiny of AI and data integrity

Summary

In its pharmaceutical outlook, NTT DATA describes an industry facing pressure from payers and regulators at the same time. Expectations for performance on digital, data and ESG measures keep rising. Meanwhile, drug pipelines are shifting toward highly scientific, high-cost therapies. Payers want proof of value in real-world use, while regulators are stepping up scrutiny of how AI is used, of data integrity and of compliance with good practice standards. The report adds that operations must become more agile and resilient as multimodal manufacturing, fragile supply chains and strict quality rules coincide with cost and access pressures. It sees trusted AI, rigorous data governance and digital twins as key responses.